Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 165

Sort by

Sort Order Select

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

Stephanie Herold, Anke Ohler, Marie-Kristin Tilch, Christian Schmidt, Michael Unterhalt, Eva Hoster, Elisabeth Hoenig, Susanne Singer, Carlo Visco, Marco Ladetto, Alessandra Tucci, Christiane Pott, Georg Hess, Martin Dreyling

Blood (2024) 144 (Supplement 1): 3042.2.

https://doi.org/10.1182/blood-2024-204691

Published: 2024

Journal Articles

Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)

Marie-Kristin Tilch, Christian Schmidt, Marek Trneny, Eva Gine, Olivier Hermine, Anke Ohler, Stephanie Herold, Marta Illenyi, Eva Hoster, Christiane Pott, Martin Dreyling, Georg Hess

Blood (2024) 144 (Supplement 1): 4422.3.

https://doi.org/10.1182/blood-2024-206931

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Blood (2024) 144 (Supplement 1): 859.

https://doi.org/10.1182/blood-2024-200604

Published: 2024

Journal Articles

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6494.

https://doi.org/10.1182/blood-2024-200002

Published: 2024

Journal Articles

Combination of the Dual Pan-PI3K/PIM Inhibitor Ibl-202 with the BCL-2 Inhibitor Venetoclax Enhances Apoptotic Priming and Is an Effective Targeted Treatment Approach in Mantle Cell Lymphoma

Anton Gaiderov, Anton Burkhard-Meier, Johannes Adrian Hildebrand, Maximilian Alexander Maurice Köstler, Gael Roue, Martin Dreyling, Elisabeth Theresa Silkenstedt

Blood (2024) 144 (Supplement 1): 5825.

https://doi.org/10.1182/blood-2024-202518

Published: 2024

Journal Articles

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Yannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie-Helene Delfau-Larue, Clémentine Sarkozy, Mary B. Callanan, Benoit Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine

Blood (2024) 144 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2024-199152

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2024-200290

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

Treatment of Relapsed/Refractory MCL

Elisabeth Silkenstedt, Martin Dreyling

Blood blood.2023022353.

https://doi.org/10.1182/blood.2023022353

Published: 2024

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, Martin Dreyling, Gianluca Gaidano, Nagesh Kalakonda, Eva Maria Gonzalez Barca, Anna Marina Liberati, Zsolt Nagy, Daniel Moik, Mirko Vukcevic, Aasim Amin, Abhishek Bakuli

Blood (2023) 142 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2023-174043

Published: 2023

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

NARROW

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Combination of the Dual Pan-PI3K/PIM Inhibitor Ibl-202 with the BCL-2 Inhibitor Venetoclax Enhances Apoptotic Priming and Is an Effective Targeted Treatment Approach in Mantle Cell Lymphoma

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Treatment of Relapsed/Refractory MCL

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only